SP-0244: From co-morbidity and toxicity to quality of life: A black hole in economic evaluations of radiotherapy?
Abstract
As a disease of the elderly, cancer poses a unique public health problem worldwide. Elderly patients with cancer are less likely to receive guideline-based treatment and/or participate in clinical trials. At the individual patient level, competing risk, perceived efficacy of treatment, and various levels of patient/physician preferences all contribute to heterogeneity in treatment decision-making. At the population level, the economic impact of this variability is significant. Costs incurred in the prevention, diagnosis, treatment and surveillance of cancer are rising at a rate disproportionate to what healthcare systems are able to afford. Cost-effectiveness research can be employed to determine the suitability of radiotherapy in elderly cancer populations through modeling or in the context of clinical trials. Using stereotactic radiotherapy in early stage lung cancer as an example, the principals of cost-effectiveness research will be explored. Concepts such as cost calculations, quality adjusted life expectancy, utilities, and incremental cost effectiveness ratios will be introduced.
Read the paper
Related studies
- A Survey on Knowledge Graphs: Representation, Acquisition, and Applications
- Toxicity of nanomaterials
- The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies
- Halogen bonding (X‐bonding): A biological perspective
- Biofilm formation at the air–liquid interface by the Pseudomonas fluorescens SBW25 wrinkly spreader requires an acetylated form of cellulose
- Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.